The “Whiskey Cavalier” actor opens up about caregiving for his mother following her ovarian cancer diagnosis.
This week, we spoke with all three of CURE’s 2019 Ovarian Cancer Heroes: Ryan Mitstifer Walton, Paula Anastasia, RN, MN, AOCN, and Shannon Westin, M.D., M.P.H.
Researchers define the genetic characteristics of ovarian tumors-- information that could lead to new opportunities for personalized therapy and may explain why screening programs for the disease haven’t been successful.
Ten years later, a woman with a BRCA1 mutation finally feels more like herself.
Understand how the rare relative of ovarian cancer is diagnosed and treated.
Treatment with the combination of Keytruda (pembrolizumab), Avastin (bevacizumab) and metronomic cyclophosphamide appeared safe and effective in women with recurrent epithelial ovarian cancer, according to results from an open-label phase 2 study.
Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.